Dashboard
Manage Tickers

CANF


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 12:09:34

d-boral-capital-maintains-buy-on-can-fite-biofarma-maintains-11-price-target
D. Boral Capital Maintains Buy on Can Fite...
09/16/2025 11:03:59

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $11 price target.

can-fite-highlights-potential-of-namodenoson-as-patient-shows-resolution-of-life-threatening-esophageal-varices-in-advanced-liver-disease
Can-Fite Highlights Potential Of Namodenos...
09/15/2025 11:06:51

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
08/22/2025 12:08:33

can-fite-hits-50-enrollment-in-phase-2a-pancreatic-cancer-study-of-namodenoson-citing-safety-profile-and-fda-orphan-drug-status
Can-Fite Hits 50% Enrollment In Phase 2a P...
07/30/2025 11:08:13

d-boral-capital-maintains-buy-on-can-fite-biofarma-maintains-10-price-target
D. Boral Capital Maintains Buy on Can Fite...
07/29/2025 13:18:04

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $10 price target.

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
07/28/2025 17:06:06

can-fite-biopharma-shares-resume-trade
Can-Fite Biopharma Shares Resume Trade
07/28/2025 16:40:36

can-fite-prices-5m-public-offering-of-833m-adss-at-060ads-plus-warrants-to-purchase-1667m-adss-for-up-to-10m-more
Can-Fite Prices $5M Public Offering Of 8.3...
07/28/2025 16:28:59

Can-Fite BioPharma Ltd.

can-fite-biopharma-shares-halted-on-code-news-pending
Can-Fite Biopharma Shares Halted On Code N...
07/28/2025 16:26:41

can-fites-piclidenoson-shows-effect-in-ucla-study-on-vascular-dementia-a-disease-with-no-approved-treatments
Can-Fite's Piclidenoson Shows Effect in UC...
07/28/2025 11:08:06

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary s...

can-fite-biopharma-to-present-update-on-ongoing-phase-iia-study-in-pancreatic-cancer-during-partnering-meetings-at-2025-bio-international-convention
Can-Fite BioPharma To Present Update On On...
06/16/2025 13:01:42

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary s...

can-fite-announces-it-has-raised-175m-for-development-of-namodenoson-and-piclidenoson-advancing-into-pivotal-phase-3-trials-in-liver-cancer-and-psoriasis
Can-Fite Announces It Has Raised $175M For...
05/05/2025 12:06:02

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule dr...

can-fite-biopharma-us-medical-centers-approach-fda-for-compassionate-use-approval-to-treat-patients-with-pancreatic-carcinoma-with-oncological-drug-namodenoson
Can-Fite BioPharma: US Medical Centers App...
04/17/2025 12:57:52

Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company...

d-boral-capital-maintains-buy-on-can-fite-biofarma-maintains-10-price-target
D. Boral Capital Maintains Buy on Can Fite...
04/15/2025 11:08:30

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $10 price target.

can-fite-announces-30m-registered-direct-offering-of-adss-at-purchase-price-of-120ads-offering-expected-to-close-on-or-about-april-15-2025
Can-Fite Announces $3.0M Registered Direct...
04/14/2025 18:31:58

RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company...

can-fite-completes-analysis-of-partnerships-says-will-generate-685m-in-projected-future-revenues-from-its-partnerships
Can-Fite Completes Analysis Of Partnership...
04/14/2025 12:33:41

can-fite-biopharma-fy24-net-loss-788m
Can-Fite BioPharma FY24 Net Loss $7.88M
04/14/2025 12:17:41

can-fite-announces-initiation-of-phase-3-psoriasis-study-for-piclidenoson-with-fda-and-ema-study-to-assess-clinical-safety-and-efficacy-co-primary-endpoints-include-pasi-75-and-spga-of-0-or-1-at-week-16-enrolment-begins-in-europe-us-and-canada-to-follow-the-psoriasis-market-is-estimated-at-30b-by-2030-and-has-shifted-significantly-to-oral-drugs
Can-Fite Announces Initiation Of Phase 3 P...
03/24/2025 13:05:26

Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company...

d-boral-capital-maintains-buy-on-can-fite-biofarma-maintains-10-price-target
D. Boral Capital Maintains Buy on Can Fite...
03/21/2025 11:13:31

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $10 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION